N-terminal pro-brain natriuretic peptide and tumor necrosis factor-α both are increased in patients with hepatitis C

Journal of Interferon and Cytokine Research

Volumn 30, Issue 5, 2010, Pages 359-363

  Antonelli, Alessandro ^a   Ferri, Clodoveo ^b   Ferrari, Silvia Martina ^a   Marchi, Santino ^a   De Bortoli, Nicola ^a   Sansonno, Domenico ^c   Chiavacci, Chiara ^a   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEART DISEASE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BIOSYNTHESIS; BLOOD; DYSPNEA; FATIGUE; GENETICS; HEPACIVIRUS; METABOLISM; MIDDLE AGED; PATHOGENICITY; PATHOPHYSIOLOGY; STANDARD;

HEPATITIS C VIRUS;

AGED; DYSPNEA; FATIGUE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952566473     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0059     Document Type: Article

References (37)

1. Antonelli A, Ferric, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. 2008. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 103 (10): 2488-2494.
2. Antonelli A, Ferric, Pampana A, Fallahi P, Nestic, Pasquini M, Marchi S, Ferrannini E. 2004. Thyroid disorders in chronic hepatitis C. Am J Med 117 (1): 10-13.
3. Bojunga J, Sarrazin C, Hess G, Zeuzem S. 2006. Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. World J Gastroenterol 12 (36): 5875-5877.
4. Cabanes L, Richaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, Dusser D. 2001. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 120 (6): 2047-2050.
5. Clerico A, Emdin M. 2004. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50 (1): 33-50.
6. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. 2004. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164 (18): 1978-1984.
7. Frustaci A, Calabrese F, Chimentic, Pieroni M, Thiene G, Maseri A. 2002. Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest 122 (4): 1348-1356.
8. Frustaci A, Chimentic, Calabrese F, Pieroni M, Thiene G, Maseri A. 2003. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107 (6): 857-863.
9. Frustaci A, Pieroni M, Chimentic. 2006. Immunosuppressive treatment of chronic non-viral myocarditis. Ernst Schering Res Found Workshop (55): 343-351.
10. Gardner RS, Chong V, Morton I, McDonagh TA. 2005. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7 (2): 253-260.
11. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. 1995. Histological grading and staging of chronic hepatitis. J Hepatol 22 (6): 696-699.
12. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. 2005. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (8): 948-954.
13. Jefic D, Lee JW, Jefic D, Savoy-Moore RT, Rosman HS. 2005. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 128 (1): 288-295.
14. Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, Pfeffer M, Rouleau JL, Stevenson LW. 2002. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (10): 1623-1629.
15. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von-Scheidt W. 2001. Role of brain natriuretic peptide in risk stratifi -cation of patients with congestive heart failure. J Am Coll Cardiol 38 (7): 1934-1941.
16. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN ; Valsartan Heart Failure Trial Investigators. 2002. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (19): 2454-2458.
17. Lecube A, Hernandez C, Genescà J, Simó R. 2006. Proinfl ammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 29 : 1096-1101.
18. Loffreda S, Muratori P, Muratori L, Mele L, Bianchi FB, Lenzi M. 2003. Enhanced monocyte Th1 cytokine production in HCVinfected cryoglobulinemic patients. J Hepatol 38 (2): 230-236.
19. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P. 2008. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430 (3): 264-268.
20. Matsumori A, Matoba Y, Sasayama S. 1995. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92 (9): 2519-2525.
21. Matsumori A, Sasayama S. 1996. Newer aspects of pathogenesis of heart failure: hepatitis C virus infection in myocarditis and cardiomyopathy . J Card Fail 2 (4 Suppl): S187-S194.
22. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. 2006. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 12 (4): 293-298.
23. Miettinen KH, Lassus J, Harjola VP, Siirilä-Waris K, Melin J, Punnonen KR, Nieminen MS, Laakso M, Peuhkurinen KJ. 2008. Prognostic role of pro- and anti-infl ammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 10 (4): 396-403.
24. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. 2002. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2): 202-209.
25. Motwani JG, McAlpine H, Kennedy N, Struthers AD. 1993. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 341 (8853): 1109-1113.
26. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. 1999. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (6 Pt 1): 1126-1132.
27. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. 2002. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 87 (2): 131-135.
28. Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz-Weiss H, Ben-Ari Z. 2007. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 149 : 126-136.
29. O'Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, Januzzi JL. 2005. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail 11 (5 Suppl): S9-14.
30. Okabe M, Fukuda K, Arakawa K, Kikuchi M. 1997. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 96 (1): 22-24.
31. Prati D, Poli F, Farma E, Picone A, Porta E, De Matteic, Zanella A, Scalamogna M, Gamba A, Gronda E, Faggian G, Livi U, Puricellic, Viganò M, Sirchia G. 1999. Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). J Med Virol 58 (2): 116-120.
32. Reis FJ, Viana M, Oliveira M, Sousa TA, Paraná R. 2007. Prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil: a pilot study. Braz J Infect Dis 11 (3): 318-321.
33. Remme WJ, Swedberg K ; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. 2001. Guidelines for the diagnosis and treatment of chronic heart failure . Eur Heart J 22 (17): 1527-1560. (Pubitemid 32801300)
34. Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, Williams R, Visvanathan K. 2006. Toll-like receptor expression in chronic hepatitis C: correlation with pro-infl ammatory cytokine levels and liver injury. Infl amm Res 55 (7): 279-285.
35. Saadoun D, Boyer O, Trébeden-Nègre H, Limal N, Bon-Durand V, Andreu M, Klatzmann D, Piette JC, Cacoub P. 2004. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 41 (6): 1031-1037.
36. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. 2000. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N -BNP) concentrations . Lancet 355 (9210): 1126-1130.
37. Zignego AL, Deny P, Feray C, Ponzetto A, Gentilini P, Tiollais P, Bréchot C. 1990. Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning. Mol Cell Probes 4 (1): 43-51.